FRI0099 Liver enzyme abnormalities after tofacitinib treatment in patients with hepatic steatosis from the rheumatoid arthritis, psoriatic arthritis and psoriasis clinical programmes
Authors: E.R. Soriano, H. Madariaga, O. Castañeda, G. Citera, E.E. Schneeberger, M.H. Cardiel, T. Hendrikx, D. Graham, H. Shi, D. Ponce de Leon
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Non-alcoholic fatty liver disease, characterised by hepatic steatosis (HS), is a major cause of chronic liver disease in many countries. Limited data are available on liver enzyme elevation in patients (pts) with HS who are receiving medications for inflammatory conditions, such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and psoriasis (PsO). Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA and PsA, and has also been studied in PsO. <h3>Objectives</h3> To describe baseline characteristics and liver enzyme abnormalities in pts from the tofacitinib RA, PsA and PsO clinical programmes with/without HS at baseline. <h3>Methods</h3> Pts randomised to the tofacitinib (5 or 10 mg twice daily; doses pooled) and placebo arms of 25 studies in the RA, PsA and PsO programmes were included in this pooled post hoc analysis. Most studies allowed or mandated concomitant treatment with disease-modifying antirheumatic drugs. HS was determined by the investigator and captured per the Medical Dictionary for Regulatory Activities term at baseline. Baseline characteristics, incidence of elevated total bilirubin, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &gt;1 x and &gt;3 x the upper limit of normal (ULN) up to Month (M) 3, and change from baseline in C-reactive protein (CRP) at M3 – all by HS at baseline – are reported. <h3>Results</h3> A total of 10 212 pts were included in the analysis. The prevalence of HS was 1.6% across indications (RA: 87/6729 [1.3%]; PsA: 27/710 [3.8%]; PsO: 45/2773 [1.6%]). Baseline characteristics were generally similar in pts with or without HS (table 1). However, baseline obesity, diabetes, triglycerides and liver enzymes were numerically higher, and CRP was numerically lower, in pts with HS than in those without HS (table 1). In both tofacitinib- and placebo-treated pts, incidence of elevated total bilirubin, AST and ALT&gt;1 x ULN up to M3 was higher in pts with HS than in those without HS, across indications (table 1). Incidence of elevated total bilirubin, AST and ALT&gt;3 x ULN up to M3 was low across indications, irrespective of HS (table 1). Among tofacitinib-treated pts, CRP was reduced at M3 in pts with or without HS, but to a lesser extent in those with HS, across indications. Among placebo-treated pts, changes in CRP were small, irrespective of HS (table 1). <h3>Conclusions</h3> In this exploratory analysis, prevalence of HS at baseline was 1.6% across the tofacitinib RA, PsA and PsO programmes. After up to 3 months of tofacitinib treatment, incidence of mildly elevated liver enzymes was higher in pts with HS than in those without HS. Incidence of severely elevated liver enzymes was low overall, and similar in pts with or without HS. Further studies are needed to evaluate the effects of tofacitinib on CRP and liver enzymes, and the potential impact on clinical response, in pts with RA, PsA or PsO who have comorbid HS. <h3>Acknowledgements</h3> Study sponsored by Pfizer Inc. Medical writing support was provided by N Divorty of CMC and funded by Pfizer Inc. <h3>Disclosure of Interest</h3> E. Soriano Grant/research support from: AbbVie, Janssen, Novartis, Pfizer Inc, UCB, Consultant for: AbbVie, Janssen, Novartis, Pfizer Inc, UCB, Speakers bureau: AbbVie, Bristol-Myers Squibb, Janssen, Novartis, Pfizer Inc, Roche, UCB, H. Madariaga: None declared, O. Castañeda Grant/research support from: AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, IQfarma, Janssen, MSD, Novartis, Periñán, Pfizer Inc, Roche, Roemmers and UCB, Consultant for: AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, IQfarma, Janssen, MSD, Novartis, Periñán, Pfizer Inc, Roche, Roemmers and UCB, Speakers bureau: AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, IQfarma, Janssen, MSD, Novartis, Periñán, Pfizer Inc, Roche, Roemmers and UCB, G. Citera Grant/research support from: Novartis and Pfizer Inc, Consultant for: AbbVie, Bristol-Myers Squibb, Janssen, Novartis and Pfizer Inc, E. Schneeberger: None declared, M. Cardiel Grant/research support from: Pfizer Inc and Roche, Consultant for: Eli Lilly and Pfizer Inc, Speakers bureau: Eli Lilly and Pfizer Inc, T. Hendrikx Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, D. Graham Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, H. Shi Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, D. Ponce de Leon Shareholder of: Pfizer Inc, Employee of: Pfizer Inc